Curium Pharma

curiumpharma.com · Chesterfield, United States of America

Curium Pharma is a global nuclear medicine company that develops, manufactures, and supplies diagnostic and therapeutic radiopharmaceuticals used primarily in oncology, cardiology, neurology, and other specialty indications. It serves hospitals, imaging centers, and healthcare providers through a network of production facilities and radiopharmacies, generating revenue from the sale and distribution of its nuclear medicine products and related services.

Revenue
$250M - $1B
Employees
1,001 - 5,000
Founded
2017
Headquarters
Chesterfield, United States of America

Curium Pharma customers on Arbolus

Total customers 12 10 current · 2 former
Reviews growth 5 new reviews since Jun 2026

Customers who reviewed Curium Pharma

Seniority of Curium Pharma customers

Most people who reviewed Curium Pharma hold Director roles (55%), followed by C-Suite (36%) and Manager (9%).

  • Director 55%
  • C-Suite 36%
  • Manager 9%

Customers sample

Other Partner Not specified NPS 10
Other Generalist C-Suite NPS 8 Will renew
Legal Leader Director NPS 5 Undecided

Employer names and spend open once the report publishes.

What 12 Arbolus experts think of Curium Pharma

Overall sentiment: Positive

The NPS distribution is heavily positive, with 78% of experts providing an NPS score of 8 to 10. Renewal intent is strong, as 88% express intent to renew, and only a small minority report uncertainty. Implementation stage data shows a majority (67%) are long-term users, with the balance in the pilot stage. Positive NPS and high renewal intent cluster among long-term, high-spend users, especially in clinical and pharma environments. Negative or neutral sentiment is isolated to pilot-phase users with uncertain renewal intentions.

Tell us when the Curium Pharma report publishes.

We'll email you once the full customer report is ready, with employer names, spend and every written answer. No account needed.

Sentiment

0 Net Promoter Score, from 12 scored reviews
  • Promoters 4
  • Passives 4
  • Detractors 4

Written answers and themes publish with the full report.

Renewal intent

Plan to renew 67%
  • Will renew 6
  • Undecided 3
  • Not renewing 0

Plan to renew, by seniority

  • C-Suite 67% 3 answers
  • Director 60% 5 answers
  • Manager 100% 1 answer
  • 8.5/10 Average score from customers who will renew
  • 6.3/10 Average score from undecided customers

Top alternatives

Most weighed by Curium Pharma customers

For people who use Curium Pharma

Do you use Curium Pharma at work?

Share your software review and get matched to paid projects. Arbolus pays you every time a client reads your review.

  • 12 customers of Curium Pharma have already contributed

Takes a few minutes. Your identity stays anonymous.